SurModics Inc. (SRDX) VP Charles W. Olson Sells 500 Shares
SurModics Inc. (NASDAQ:SRDX) VP Charles W. Olson sold 500 shares of the firm’s stock in a transaction that occurred on Friday, November 25th. The stock was sold at an average price of $26.02, for a total transaction of $13,010.00. Following the transaction, the vice president now directly owns 27,245 shares of the company’s stock, valued at $708,914.90. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Shares of SurModics Inc. (NASDAQ:SRDX) opened at 24.90 on Tuesday. The firm has a market cap of $325.89 million, a P/E ratio of 32.76 and a beta of 0.98. SurModics Inc. has a one year low of $17.45 and a one year high of $30.75. The firm’s 50-day moving average price is $26.64 and its 200 day moving average price is $26.23.
SurModics (NASDAQ:SRDX) last issued its quarterly earnings results on Wednesday, November 16th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.09 by $0.17. SurModics had a return on equity of 15.98% and a net margin of 13.99%. The firm had revenue of $18.20 million for the quarter, compared to analyst estimates of $16.09 million. During the same period in the previous year, the firm earned $0.30 earnings per share. The company’s revenue was up 4.6% compared to the same quarter last year. Analysts predict that SurModics Inc. will post $1.04 EPS for the current year.
A number of institutional investors have recently modified their holdings of SRDX. Prudential Financial Inc. raised its position in shares of SurModics by 1.0% in the second quarter. Prudential Financial Inc. now owns 46,622 shares of the company’s stock valued at $1,095,000 after buying an additional 460 shares during the period. Bank of Montreal Can acquired a new position in shares of SurModics during the second quarter valued at about $190,000. Gabelli Funds LLC raised its position in shares of SurModics by 2.4% in the second quarter. Gabelli Funds LLC now owns 128,626 shares of the company’s stock valued at $3,020,000 after buying an additional 3,000 shares during the period. Emerald Acquisition Ltd. acquired a new position in shares of SurModics during the second quarter valued at about $4,581,000. Finally, Ameriprise Financial Inc. raised its position in shares of SurModics by 6.7% in the second quarter. Ameriprise Financial Inc. now owns 65,348 shares of the company’s stock valued at $1,535,000 after buying an additional 4,132 shares during the period. 88.55% of the stock is currently owned by hedge funds and other institutional investors.
SRDX has been the subject of several analyst reports. Sidoti cut shares of SurModics from a “buy” rating to a “neutral” rating and set a $33.00 target price for the company. in a research note on Thursday, October 6th. Zacks Investment Research raised shares of SurModics from a “hold” rating to a “buy” rating and set a $32.00 target price for the company in a research note on Thursday, October 20th. Finally, Barrington Research cut shares of SurModics from an “outperform” rating to a “market perform” rating in a research note on Monday, November 21st.
SurModics, Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company is focused on to transform its medical device business from being a provider of coating technologies to offering whole product solutions to medical device customers.
Receive News & Stock Ratings for SurModics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SurModics Inc. and related stocks with our FREE daily email newsletter.